- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05783206
Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19
Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 ® Inhalation in Adult Outpatients With Mild COVID-19.
The aim of this study is to evaluate the effectiveness and safety of MIR 19 ® in preventing development of moderate and/or severe course of the disease in mild COVID-19 outpatients.
Primary endpoint:
The proportion of patients with the development of moderate or severe COVID-19 disease (in accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian Federation, version 14 of 27.12.2021 or current at the time of the study) by the 28th day of observation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is Phase 2b-3 multi-center controlled randomized study to assess the efficacy and safety of MIR 19 ® via 7 days treatment in a dose of 5.55 mg/day of participants with symptomatic mild COVID-19 who did not require hospitalisation.
The MIR 19® is a complex of siRNA, targeting Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) RNA-dependent RNA polymerase (RdRp) and peptide dendrimer (KK-46).
This study involved 2 cohorts who received:
- 5.5 mg of the MIR 19 ® per day via inhalation route plus standard therapy which included symptomatic treatment, without any etiotropic drugs.
- Standard therapy which included symptomatic treatment as well as etiotropic drugs except MIR 19 ®.
All subjects will undergo scheduled safety and efficacy assessments as outpatients to the end of the follow-up period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 115478
- NRC Institute of Immunology FMBA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women over the age of 18 who have been diagnosed with COVID-19 and who need therapy on an outpatient basis according to the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)"by Ministry of Health of the Russian Federation. Version 14 from 12/27/2021.
- Able to give informed consent and attend all study visits
- Duration of the disease from the first symptoms (presence of at least one of the following symptoms: fever, cough, myalgia, weakness, shortness of breath, headache, nausea, stool disorders, loss of appetite) up to the day of screening no more than 5 days.
- Negative pregnancy test for women with preserved reproductive potential
- Participants must agree to use the reliable contraception while on study medication and for posttrial contraception for 3 month
- The patient's ability to inhale the experimental drug
Exclusion Criteria:
- Respiratory rate is more than 22 / min
- Oxygen saturation - SpO2 ≤ 94%.
- Decreased level of consciousness, agitation.
- Unstable hemodynamics (systolic blood pressure less than 100 mmHg or diastolic blood pressure less than 60 mmHg).
- Long-term systemic corticosteroid exposure.
- Autoimmune or inflammatory diseases (systemic / localized), as well as oncological diseases.
- Symptoms of moderate, severe or critical COVID-19 at the time of screening
- Positive blood tests for HIV, hepatitis B and С, syphilis.
- Pregnancy and breast-feeding.
- Previous adverse reactions to the active substance and/or excipients included in the drug
- Chronic diseases of the cardiovascular system
- Type 1 diabetes.
- The following laboratory parameters are excluded: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total and direct bilirubin >4 x upper limit of normal (ULN);
- C-reactive protein (CRP) level > 10 mg/L.
- Participation in other investigational drug or device clinical trials within 90 days prior to screening.
- History of alcohol, drug or chemical abuse
- Previous hospitalizations associated with the development of moderate and severe COVID-19.
- Mental illness.
- Receipt of plasma from a person who recovered from COVID-19 (convalescent plasma) up to 14 days before participating in the study, vaccination against SARS-CoV-2 less than 4 weeks before randomization.
- Any conditions that, according to the researcher's, may be a contraindication to the participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MIR 19 ®
MIR 19 ® was used in a single dose of 1.85 mg for 3 inhalations per day at intervals of 6-7 hours for 7 days in addition to standard therapy without use of any etiotropic drugs. Standard therapy included: - paracetamol - 1-2 tablets (500-1000 mg) 2-3 times a day (if body temperature ≥38.0°) |
MIR 19 ® contains anti-SARS-CoV-2 siRNAs/KK-46 (peptide dendrimer) complexes for inhalation use. In the experimental groups treated with MIR 19 ®, the therapy included symptomatic treatment without use of any etiotropic drugs. |
Active Comparator: Standard therapy
Standard therapy included:
|
Therapy carried out in accordance with the current version of the temporary methodological recommendations of the Ministry of Health of the Russian Federation for the treatment of COVID-19 infection.
This therapy included symptomatic treatment as well as etiotropic drugs (except MIR 19 ®)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Moderate or severe COVID-19
Time Frame: 28th day of observation
|
The proportion of patients with the development of moderate or severe COVID-19 disease (in accordance with the criteria specified in the Interim Guidelines "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)" by the Ministry of Health of the Russian Federation, version 14 of 27.12.2021
or current at the time of the study)
|
28th day of observation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Etiotropic therapy
Time Frame: 28th day of observation
|
The proportion of patients required another etiotropic therapy COVID-19 during the study.
|
28th day of observation
|
Improvement / disappearance of COVID-19 symptoms
Time Frame: 28th day of observation
|
Time to clinical improvement / disappearance of symptoms according to the scale of assessment of the severity of symptoms of the disease
|
28th day of observation
|
Duration of COVID-19 symptoms
Time Frame: 28th day of observation
|
Duration of clinical symptoms of COVID-19 disease (fever, cough, myalgia, weakness, shortness of breath, headache, nausea, stool disorders, loss of appetite, anosmia, ageusia) according to the patient's diary.
|
28th day of observation
|
Moderate COVID-19
Time Frame: 28th day of observation
|
Proportion of patients with moderate COVID-19.
|
28th day of observation
|
Severe COVID-19
Time Frame: 28th day of observation
|
Proportion of patients with severe COVID-19.
|
28th day of observation
|
Critical COVID-19
Time Frame: 28th day of observation
|
Proportion of patients with critical COVID-19
|
28th day of observation
|
Hospitalization
Time Frame: 28th day of observation
|
Proportion of hospitalized patients
|
28th day of observation
|
Death rate
Time Frame: 28th day of observation
|
The proportion of deaths during the study
|
28th day of observation
|
Worsening of COVID-19 symptoms
Time Frame: 28th day of observation
|
The proportion of patients with worsening of COVID-19 clinical symptoms during the study by at least 1 point
|
28th day of observation
|
Severity of COVID-19 symptoms
Time Frame: 28th day of observation
|
Assessment of the severity of COVID-19 symptoms (nasal congestion, sore throat, shortness of breath, cough, weakness, myalgia, headache, chills, fever, nausea, vomiting, diarrhea, anosmia, ageusia) according to the patient's diary.
|
28th day of observation
|
Results of polymerase chain reaction (PCR)
Time Frame: 28th day of observation
|
The proportion of patients with negative PCR to SARS-CoV-2 at visits 4, 5
|
28th day of observation
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 04-SiCoV/KK46-01/22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on MIR 19 ®
-
National Research Center - Institute of Immunology...St. Petersburg Research Institute of Vaccines and SeraCompletedCOVID-19Russian Federation
-
Washington University School of MedicineTerminatedAbdominal SurgeryUnited States
-
Chang Gung Memorial HospitalUnknownStiffness of Shoulder, Not Elsewhere ClassifiedTaiwan
-
Azienda Ospedaliera Universitaria Mater Domini,...Associazione Italiana per la Ricerca sul CancroCompletedAdvanced Solid Tumor | Hepatocarcinoma | Multiple Myeloma, RefractoryItaly
-
miR Scientific LLCActive, not recruitingProstate CancerPuerto Rico
-
Islamia University of BahawalpurGerman University in CairoCompletedMyocardial Infarction, AcuteEgypt
-
NanomixCompleted
-
Miltenyi Biomedicine GmbHCity of Hope Comprehensive Cancer CenterNot yet recruitingHematological Malignancies
-
Research Institute for Biological Safety ProblemsNational Scientific Center for Phthisiopulmonology of the Republic of KazakhstanCompletedCovid19 | Vaccine Adverse Reaction | SARS-CoV InfectionKazakhstan
-
Research Institute for Biological Safety ProblemsCity polyclinic No. 4 of the of Almaty Ministry of Healthcare of the Republic... and other collaboratorsCompletedCovid19 | Vaccine Adverse Reaction | SARS-CoV InfectionKazakhstan